Federal psilocybin rescheduling will not advance past DEA petition review stage before January 1, 2028

Psilocybin (the active compound in magic mushrooms) is currently a Schedule I controlled substance, the most restricted category. Moving it to a less restricted schedule requires the Drug Enforcement Administration (DEA) to officially change its rules, or Congress to pass a law. The DEA has built-in institutional reasons to resist this change, and Congress has not scheduled floor time to debate it. Meanwhile, states like Oregon and Colorado are moving ahead on their own.

DEA institutional resistance to Schedule I rescheduling is structural and well-documented. The current Congressional calendar leaves no floor time for scheduling legislation. No companion bills with majority co-sponsorship exist. State-level legalization (Oregon, Colorado) will continue to outpace federal action. Resolves FALSE only if DEA publishes a Notice of Proposed Rulemaking to reschedule psilocybin or Congress passes floor-vote legislation.